세계의 발작성야간혈색뇨증(PNH) 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size is anticipated to grow from USD 4.88 Billion in 2024 to USD 13.31 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 11.77% during the forecast period of 2026 to 2033.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.

The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.

Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Treatment Type

• Complement Inhibitors
• Iron Therapy
• Immunosuppressant Drugs
• Bone Marrow Transplantation
• Other Treatment Types

By Route Of Administration

• Oral
• Parenteral

By Age Group

• Pediatric
• Adult

By End-use

• Hospitals
• Specialty clinics
• Homecare settings
• Other end-users
• COMPANIES PROFILED
• Amgen Inc.
• Apellis Pharmaceuticals Inc.
• AstraZeneca Plc
• Children's National Hospital
• F. Hoffmann-La Roche Ltd.
• Memorial Sloan Kettering Cancer Center
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Teva Pharmaceuticals Industries Ltd.
• UCLA Health
• University of Rochester Medical Center
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment Type
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By End-use
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

• 5.1. Overview By Treatment Type
• 5.2. Historical and Forecast Data Analysis By Treatment Type
• 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
• 5.4. Iron Therapy Historic and Forecast Sales By Regions
• 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
• 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data Analysis By Route of Administration
• 6.3. Oral Historic and Forecast Sales By Regions
• 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data Analysis By Age Group
• 7.3. Pediatric Historic and Forecast Sales By Regions
• 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-use
• 8.2. Historical and Forecast Data Analysis By End-use
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Specialty clinics Historic and Forecast Sales By Regions
• 8.5. Homecare settings Historic and Forecast Sales By Regions
• 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

• 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Amgen Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Apellis Pharmaceuticals Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. AstraZeneca Plc
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Children'S National Hospital
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. F. Hoffmann-La Roche Ltd.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Memorial Sloan Kettering Cancer Center
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Novartis AG
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Pfizer Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Regeneron Pharmaceuticals Inc.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Teva Pharmaceuticals Industries Ltd.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. UCLA Health
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. University Of Rochester Medical Center
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies